StreetInsider.com News Articles

OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

Fri, 04 Oct 2024 16:59:09 -0400

OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the

OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

Fri, 04 Oct 2024 16:59:09 -0400

OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the

OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

Fri, 04 Oct 2024 16:59:09 -0400

OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the

OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

Fri, 04 Oct 2024 16:59:09 -0400

OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the

OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

Fri, 04 Oct 2024 16:59:09 -0400

OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the

OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

Fri, 04 Oct 2024 16:59:09 -0400

OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq:

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Fri, 04 Oct 2024 16:57:00 -0400

-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer

-- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024

-- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026

-- Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024

BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: